No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Aadi Bioscience Rockets 72% on Key Updates
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"
[Brokerage Focus] CEB International raises WUXI BIO (02269) Target Price by 68.5%. Global Biomedical financing recovery is Bullish on its valuation and performance recovery.
Jingwu Financial News | According to the Research Reports from CCB International, it is expected that the biosafety bill will most likely fail in legislation, which is Bullish for WUXI BIO (02269) to continue achieving performance growth in a relatively stable Operation environment. With the recovery of Global Biomedical financing, the bank is Bullish on the Company Valuation and performance recovery. The bank maintains a Buy rating for WUXI BIO and raises the Target Price based on DCF valuation to HKD 22.88 (previous value: HKD 13.58). The bank expects WUXI BIO's 2024E/25E/26E revenue to grow year-on-year by 7.1%/12.4%/13.9%, with adjusted Net income growing year-on-year by 0.8%/1.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
The concept of contract research organizations started positively, wuxi bio (02269) rose by 13.03%, and the U.S. Biosafety Act was not included in the 2025 Fiscal Year Defense Authorization Act.
Jinwu Financial News | The contract research organizations concept started off positively, as of the time of publication, Wuxi Bio (02269) is up 13.03%, Wuxi AppTec (02359) is up 11.72%, Pharmaron (03759) is up 9.14%, Genscript Bio (01548) is up 4.98%, and Tigermed (03347) is up 4.87%. In terms of news, on December 7 local time in the USA, the final agreement text of the 2025 fiscal year National Defense Authorization Act (NDAA) released by the military committees of both the House and Senate did not include the biosafety act. Morgan Stanley stated, USA
No Data
